Effects of the NIK aly Mutation on NF-kappa B Activation by the Epstein-Barr Virus Latent Infection Membrane Protein, Lymphotoxin beta  Receptor, and CD40*

Micah A. Luftig, Ellen Cahir-McFarland, George MosialosDagger, and Elliott Kieff§

From the Departments of Microbiology and Molecular Genetics and Medicine, Program in Virology, Harvard Medical School, Boston, Massachusetts, 02115

Received for publication, February 23, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Homozygosity for the aly point mutation in NF-kappa B-inducing kinase (NIK) results in alymphoplasia in mice, a phenotype similar to that of homozygosity for deletion of the lymphotoxin beta  receptor (LTbeta R). We now find that NF-kappa B activation by Epstein-Barr virus latent membrane protein 1 (LMP1) or by an LMP1 transmembrane domain chimera with the LTbeta R signaling domain in human embryonic kidney 293 cells is selectively inhibited by a wild type dominant negative NIK comprised of amino acids 624-947 (DN-NIK) and not by aly DN-NIK. In contrast, LMP1/CD40 is inhibited by both wild type (wt) and aly DN-NIK. LMP1, an LMP1 transmembrane domain chimera with the LTbeta R signaling domain, and LMP1/CD40 activate NF-kappa B in wt or aly murine embryo fibroblasts. Although wt and aly NIK do not differ in their in vitro binding to tumor necrosis factor receptor-associated factor 1, 2, 3, or 6 or in their in vivo association with tumor necrosis factor receptor-associated factor 2 and differ marginally in their very poor binding to Ikappa B kinase beta  (IKKbeta ), only wt NIK is able to bind to IKKalpha . These data are compatible with a model in which activation of NF-kappa B by LMP1 and LTbeta R is mediated by an interaction of NIK or a NIK-like kinase with IKKalpha that is abrogated by the aly mutation. On the other hand, CD40 mediates NF-kappa B activation through a kinase that interacts with a different component of the IKK complex.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

NF-kappa B-inducing kinase, NIK,1 is a TRAF2-interacting mitogen-activated protein kinase kinase kinase that potently activates NF-kappa B (1-3). NIK can activate the Ikappa B kinase (IKK) complex by phosphorylating serine 176 in the activation loop of IKKalpha and may directly phosphorylate IKKbeta (4-6). NIK activation of IKK results in phosphorylation of Ikappa Balpha serines 32 and 36, Ikappa Balpha ubiquitination and degradation, and NF-kappa B translocation to the nucleus. Overexpression of a catalytically inactive mutant of NIK (NIK K429A/K430A) has a dominant negative effect on NF-kappa B activation through most known stimuli including LMP1, TNFR1, TNFR2, RANK, hTollR, CD3/CD28, interleukin-1R, human T-cell lymphotropic virus-1 Tax, and LPS (1, 7-11).

NIK has an essential role in lymphoid organ development (12). The aly mutation results in a single amino acid change of glycine to arginine at mNIK codon 855 and can be rescued by transgenic expression of wild type NIK (12). Alymphoplasia (aly/aly) mice not only lack lymph nodes and Peyer's patches but also have abnormal spleen and thymus development, low serum Ig levels, and impaired B cell proliferation in response to LPS or CD40L (12, 13). LTbeta R-/- and aly/aly mice have similar developmental and immunological defects, and NIK has been implicated in LTbeta R-mediated activation of NF-kappa B (14, 15). Indeed, LTbeta R up-regulation of VCAM-1 is abnormal in aly/aly murine embryo fibroblasts (15). Also, CD40L-induced phosphorylation of Ikappa Balpha is abnormal in B lymphocytes from aly/aly mice, although phosphorylation of Ikappa Balpha in dendritic cells is normal (13).

Epstein-Barr virus (EBV) latent infection of human B lymphocytes causes B lymphocyte proliferation through expression of nuclear proteins and an integral membrane protein, LMP1, which mimics constitutively activated TNFRs (16). LMP1 has a short, arginine-rich, N-terminal cytoplasmic domain that is important for anchoring the first transmembrane domain, six hydrophobic transmembrane domains that mediate LMP1 aggregation in lipid rafts, and a 200-amino acid C-terminal cytoplasmic domain that has two sites that mediate EBV-induced B cell proliferation and NF-kappa B activation (for review see Ref. 17). One site binds TRAF 3, 1, 2, and 5, whereas the second site binds TNFR-associated death domain protein (18, 19). NF-kappa B activation from either site is inhibited by overexpression of K429A/K430A kinase-negative DN-NIK (7). Thus, previous data are consistent with NIK having a significant role in LMP1 activation of NF-kappa B. The experiments reported here further investigate the role of NIK and of the aly mutation in NF-kappa B activation by LMP1, LTbeta R, and CD40.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression Vectors-- Wild type hNIK624-947 was amplified by PCR of hNIK cDNA with oligonucleotides NF3 (5' GGATCCCCTCTCACAGCCCAGGCCATC 3') and NR1 (5' GAATTCTTAGGGCCTGTTCTCCAGCTGGC 3') that included BamHI and EcoRI sites and cloned into pGEX-2TK (Amersham Pharmacia Biotech) for bacterial expression. The aly hNIK624-947 GST mutant was made by site-directed mutagenesis of the hNIK codon 860 with primers NF8 (5' AGCTATTTCAATCGGGTGAAAGTCCAAATA CAG 3') and NR6 (5' CTGTATTTGGACTTTCACCCGATTGAAATAGCTTGG 3') followed by PCR with the BamHI and EcoRI primers and cloned into pGEX-2TK. The BamHI/EcoRI fragments were also used to make wt and aly DN-NIK for mammalian expression by subcloning into pCDNA3 (Invitrogen). Plasmids encoding TRAF1, TRAF2, TRAF3, IKKalpha , IKKbeta , LMP1, CD40, and LMP1/CD40 have been described (7, 18, 20). The pCR-F-mTRAF6 plasmid was obtained from Dr. J. Inoue. The LMP1/LTbeta R construct was made by cloning the cytoplasmic domain from LTbeta R into the previously described LMP1 pCDNA3 construct.

Cell Lines-- 293 and 293T cells were cultured as previously described (7). MEFs from aly/aly and wild type mice were obtained from Dr. T. Honjo. Primary MEFs were not amenable to transfection. Therefore, cells were infected with a human papilloma virus 16 E6/E7 retrovirus containing a neomycin resistance cassette (obtained from Dr. P. Howley), and transformed cell lines were selected for G418 resistance and growth advantage. Cells were subsequently grown in Dulbecco's modified Eagle's medium with 20% fetal calf serum and antibiotics.

Transfections and Reporter Gene Assays-- Transfections and reporter assays (7) were done with 350 ng per well of the 3xNF-kappa B-luc reporter plasmid and 350 ng per well of pGK-beta -galactosidase as a transfection control. Measurements of luciferase and beta -galactosidase activities were done with an Optocomp I luminometer (MGM Systems).

[35S]Met in Vitro Translations and GST Pulldowns-- In vitro transcription and translation reactions (IVTs) were done with (18) 1 µg of expression plasmid for TRAF1, 2, 3, or 6 diluted into 8 µl of distilled H2O and 40 µl of a TnT quick-coupled rabbit reticulocyte lysate in vitro transcription and translation system (Promega) in the presence of 2 µl of [35S]Met (10 µCi/µl). After incubation at 30 °C for 1 h and preclearing with GST-bound glutathione-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4 °C, IVTs were split into fractions for incubation with ~5 µg of wt or aly NIK-GST fusion proteins or GST alone. The GST/IVT mix was rotated at 4 °C for 1 h, beads were washed 3-5 times with GST lysis buffer, and boiled in 30 µl of SDS-PAGE loading buffer. The samples were analyzed by SDS-PAGE and phosphorimaging (Molecular Dynamics).

Immune Precipitations-- For transfections, 293T cells were seeded in 6-well plates at 5 × 105 cells/well, and 24 h later 3 wells were transfected with 1 µg of pCDNA3-F-TRAF2 or pRK5-myc-IKKalpha per well and 2, 3, or 4 µg/well of wt or aly DN-NIK or pCDNA3 for each immune precipitation. Cells were lysed in Nonidet P-40 lysis buffer (1% Nonidet P-40, 150 mM NaCl, 0.5 mM EDTA, 20 mM Tris, pH 7.5) containing phenylmethylsulfonyl fluoride (1 mM) and aprotinin (22 µg/ml) for 30 min on ice. Following lysis, cells were centrifuged at high speed for 10 min, precleared with protein G-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4 °C, normalized for total protein concentration, and 2 µg of TRAF2 (C-20; Santa Cruz Biotechnology) antibody or 30 µl of M2 beads (Amersham Pharmacia Biotech) were added. After rotation for 1 h at 4 °C for C-20, protein G-Sepharose was added to the samples for an additional 1 h. Immune precipitates were washed 3-5 times with Nonidet P-40 lysis buffer. Samples were denatured in SDS-PAGE loading buffer and subjected to SDS-PAGE followed by immunoblotting (IB). IB antibodies were H-248 (NIK; Santa Cruz Biotechnology), M-110 (IKKalpha ; Santa Cruz Biotechnology), 9E10 (Myc; see Ref. 21), and C-20 (TRAF2; Santa Cruz Biotechnology).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Effects of wt or aly DN-NIK on EBV LMP1-mediated Activation of NF-kappa B-- LMP1 expression in 293T cells strongly activated NF-kappa B as measured by a co-transfected reporter with three NF-kappa B sites from the major histocompatibility complex I promoter upstream of luciferase and a pGK-beta -galactosidase control plasmid (see Fig. 1 and Refs. 7, 22, and 23). LMP1-mediated NF-kappa B activation was inhibited in a dose-dependent manner by co-expression of the wt DN-NIK fragment (aa 624-947) (Fig. 1A). In contrast to the effect of wt DN-NIK, co-expression of the DN-NIK containing the aly point mutation G860R did not inhibit LMP1 activation of NF-kappa B (Fig. 1B). wt and aly DN-NIK were expressed at equivalent levels, beta -galactosidase levels did not vary more than 2-fold, and LMP1 expression was not affected by either wt or aly DN-NIK (Fig. 1C), excluding an artifactual basis for the differential effect. Thus, LMP1 activation of NF-kappa B is resistant to aly but not to wt DN-NIK as had been previously noted for LTbeta R (12). Similar results were obtained in multiple experiments in 293 and 293T cells.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of LMP1-mediated NF-kappa B activation by wt DN-NIK but not aly DN-NIK. A and B, 293T cells were cotransfected with 50 ng of LMP1 expression plasmid pCDNA3-LMP1, 350 ng of the NF-kappa B reporter construct 3xkappa B-luc, and 350 ng of pGK-beta -galactosidase. Also, increasing amounts (0.1, 1, and 2 µg) of either wt or aly DN-NIK were transfected. Raw luciferase values were divided by beta -galactosidase values to control for transfection efficiency. The effects of DN-NIK on LMP1-mediated NF-kappa B activation are expressed as a percentage of the activation with LMP1 transfected alone. Values represent the average from three independent experiments. C, lysates from transfected cells were subjected to SDS-PAGE and IB using either LMP1 or NIK antibody. For LMP1 IB, lanes 1-4 represent cells transfected with LMP1 plus 0, 0.1, 1, or 2 µg of wt DN-NIK. No change in expression of LMP1 was detected in the presence of aly DN-NIK (not shown). For NIK, IB of lysates from cells transfected with LMP1 and 0, 0.1, or 2 µg of wt DN-NIK (lanes 1-3) and 0.1 or 2 µg of aly DN-NIK (lanes 4-5) are shown.

Effects of wt or aly DN-NIK on LTbeta R and CD40 Activation of NF-kappa B-- To evaluate whether the differential effect of the wt and aly DN-NIK is specific for LMP1 and LTbeta R signaling as opposed to other TNFRs, the effect of wt and aly DN-NIK on NF-kappa B activation by LMP1, LTbeta R, and CD40 was assayed in 293T and 293 cells. The LMP1 transmembrane domains were used to provide constitutive, ligand-independent receptor aggregation. Isogenic expression constructs were made in which the LMP1 C-terminal cytoplasmic domain was replaced with the LTbeta R or CD40 C-terminal cytoplasmic domains. LMP1 and the LMP1/LTbeta R chimera activated NF-kappa B, and the activation was inhibited by wt but not by aly DN-NIK (see Fig. 1 and Fig. 2, A and B). wt and aly DN-NIK did not affect LMP1/LTbeta R expression, and beta -galactosidase levels did not vary more than 2-fold (Fig. 2C and data not shown). These results are consistent with the previous observation that NF-kappa B activation following LTbeta R overexpression is inhibited by wt but not by aly DN-NIK (12). In contrast to the effects of wt but not aly DN-NIK on LMP1 or LMP1/LTbeta R activation of NF-kappa B, NF-kappa B activation mediated by an LMP1/CD40 cytoplasmic domain chimera or by CD40 overexpression was inhibited by both wt and aly DN-NIK (Fig. 3, A and B and data not shown). CD40 and LMP1/CD40 expression were not affected by either wt or aly DN-NIK (Fig. 3C and data not shown). These data support a model in which LMP1 and LTbeta R activation of NF-kappa B involves a downstream molecular interaction that can be inhibited by wt hNIK aa 624-947 but not by the corresponding fragment with the glycine to arginine mutation at codon 860. 


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of LMP1/LTbeta R-mediated NF-kappa B activation by wt DN-NIK but not aly DN-NIK. A and B, experiments were performed as in Fig. 1, except that 5 µg of LMP1/LTbeta R was used instead of LMP1. Results are averages from three independent experiments and are represented as a percent of the NF-kappa B activation observed with LMP1/LTbeta R alone. C, IB for FLAG-tagged LMP1/LTbeta R using M2/M5 anti-FLAG antibody (Sigma). Lanes 1-3 represent cells transfected with LMP1/LTbeta R alone or with 0.1 or 2 µg of wt DN-NIK. Expression of LMP1/LTbeta R was identical with aly DN-NIK (not shown). Equivalent amounts of wt as compared with aly DN-NIK were detected by anti-NIK IB (not shown).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   CD40-mediated NF-kappa B activation is inhibited by both wt and aly DN-NIK. A and B, this experiment was identical to that shown in Fig. 1, except that 1 µg of CD40 was transfected instead of LMP1. The data shown are from one representative experiment of two with CD40 and three with LMP1/CD40 (not shown). C, IB of CD40 from cells transfected with CD40 alone (lane 1) or with CD40 plus 0.1 or 2 µg of wt DN-NIK (lanes 2 and 3). Identical expression of CD40 was seen with CD40 plus aly DN-NIK (not shown).

LMP1, LMP1/LTbeta R, and LMP1/CD40 Activation of NF-kappa B in wt and aly/aly MEFs-- To evaluate the direct effect of the aly mutation on LMP1, LTbeta R, and CD40 activation of NF-kappa B, NF-kappa B activation by isogenic LMP1, LMP1/LTbeta R, and LMP1/CD40 was assessed in wt and aly/aly MEFs using the co-transfected NF-kappa B-dependent luciferase reporter and control pGK-beta -galactosidase expression plasmids. Before initiating this series of experiments, the MEFs were first transformed with a human papilloma virus 16 E6 and E7-expressing retrovirus so as to enhance their growth and transfection efficiency (24). The surprising result was that LMP1, LMP1/LTbeta R, and LMP1/CD40 activated NF-kappa B similarly in wt and aly/aly MEFs indicating that NIK is not essential for NF-kappa B activation by these receptors in fibroblasts (Fig. 4). Thus, the insensitivity of LMP1 and LMP1/LTbeta R to aly DN-NIK inhibition of NF-kappa B activation is not because of a specific and exclusive dependence of these receptors on wt NIK for NF-kappa B activation.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   LMP1, LMP1/LTbeta R, and LMP1/CD40 activate NF-kappa B at an equivalent level in wt and aly MEFs. LMP1 (100 ng), LMP1/LTbeta R (5 µg), or LMP1/CD40 (100 ng) were transfected into either wt (black-square) or aly/aly () MEFs, along with 3xkappa B-luc and pGK-beta -galactosidase. Luciferase assays were performed as in Fig. 1. NF-kappa B activation relative to control plasmid is shown for one representative of three independent experiments.

aly NIK Interacts with TRAFs in Vitro and in Vivo-- The aly mutation at codon 860 falls within both the TRAF binding domain (aa 624-947) and the IKK binding domain (aa 735-947) of hNIK (1, 25) (Fig. 5A). The aly/aly phenotype is presumed to be because of the failure of aly NIK to interact with TRAFs (25). To more precisely determine the biochemical basis for the aly effect on NIK interactions, we compared the in vitro and in vivo binding of wt and aly NIK to TRAFs.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   wt and aly NIK bind to TRAFs in an equivalent manner. A, a schematic diagram of NIK is shown. N-terminal regions were recently defined to play a role in regulating NIK activity by preventing the interaction between the C terminus of NIK and IKKalpha (39). The ATP binding pocket within the conserved MAP kinase domain is ablated by the K429A/K430A mutation (1). Thr 559 is the critical residue in the activation loop of the kinase domain that is phosphorylated by Tpl2 and is required for kinase activation (3). The region from aa 624-947 has been defined as the necessary and sufficient TRAF binding domain (1),2 whereas aa 735-947 within this domain is necessary and sufficient for IKKalpha binding (3). The alymphoplasia phenotype is caused by a single point mutation (Gly to Arg) occurring at amino acid 855 in mNIK (12) and is in a highly conserved region in hNIK at amino acid 860. BR, basic region; PRR, proline-rich region. B, [35S]methionine-labeled, in vitro-translated TRAFs 1, 2, and 3 or mTRAF6 were incubated with wt NIK624-947-GST, aly NIK624-947-GST, or GST alone. The 10% input lane indicates 10% of the total IVT reaction lysate used for each binding assay. Samples were resolved by SDS-PAGE, and binding was analyzed by phosphorimaging. C, 293T cells were co-transfected with F-TRAF2 and either wt or aly DN-NIK. F-TRAF2·NIK complexes were immunoprecipitated with anti-FLAG resin (M2; Sigma) followed by IB with anti-NIK antibody. 2% of whole cell lysates were probed with anti-TRAF2 and anti-NIK antibody.

hTRAFs 1, 2, and 3 and mTRAF6 were transcribed and translated with radiolabeled [35S]methionine, and their ability to bind in vitro to equal amounts of wt or aly hNIK aa 624-947 fused to GST (NIK624-947-GST) was assessed. The aly mutation did not affect TRAFs binding to NIK624-947-GST in vitro (Fig. 5B). However, TRAFs differed in their binding to NIK624-947-GST; TRAF1 and -2 bound to NIK624-947-GST at the 10 to 15% level, whereas less than 3% of TRAF3 or -6 bound to NIK624-947-GST (Fig. 5B).

Because TRAF2 is an important mediator of TNFR1-induced NF-kappa B activation (26), TRAF2 associations with wt and aly NIK were evaluated in 293 cells that were co-transfected with a FLAG-tagged TRAF2 expression construct and either wt or aly DN-NIK (aa 624-947). F-TRAF2 was immune-precipitated using M2-conjugated Sepharose beads, and the complexes were blotted for the presence of NIK. F-TRAF2 consistently brought down equivalent amounts of wt or aly DN-NIK (Fig. 5C). These data indicate that the aly/aly phenotype is unlikely to be because of the previously postulated inability of TRAFs to engage and associate with aly NIK.

Differential Association of wt and aly NIK with IKKalpha and IKKbeta -- hNIK aa 735-947 is not only part of the domain that binds to TRAFs but is also a sufficient domain for interaction with IKKalpha (3, 27). hNIK aa 735-947 efficiently competes with wt NIK for binding to IKKalpha and is a dominant negative inhibitor of TNF-mediated NF-kappa B activation (3). Surprisingly, only wt but not aly NIK624-947-GST was able to pull down Myc-IKKalpha from lysates of 293T cells in which Myc-IKKalpha was expressed. About 10% of the Myc-tagged IKKalpha bound to wt NIK624-947-GST, whereas binding to similar amounts of aly NIK624-947-GST was below the limits of detection (Fig. 6A).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 6.   wt and aly NIK bind to IKKbeta ; however aly NIK does not bind to IKKalpha . A, wt NIK624-947-GST, aly NIK624-947-GST, or GST were used to precipitate either Myc-IKKalpha or F-IKKbeta from transfected 293T cells. GST-bound IKKs were subjected to SDS-PAGE followed by IB for the appropriate tag. IB with IKKalpha antibody (M110; Santa Cruz Biotechnology) resulted in an identical result (data not shown). B, 293T cells co-transfected with the indicated amounts of wt or aly DN-NIK, along with a constant amount of Myc-IKKalpha expression vector, and were immunoprecipitated with anti-myc antibody followed by IB with anti-NIK antibody. Lysates contained equivalent amounts of IKKalpha and DN-NIK proteins (not shown).

In similar experiments, the binding of FLAG-tagged IKKbeta expressed in 293T cells to wt or aly NIK624-947-GST was assessed. As reported for full-length NIK (27), FLAG-tagged IKKbeta bound very weakly to wt NIK624-947-GST, at a level of about 1% of input IKKbeta (Fig. 6A). Binding of F-IKKbeta to aly NIK624-947-GST was about half the level of binding to wt and about twice as strong as to GST alone (Fig. 6A).

To evaluate the association of Myc-IKKalpha with wt or aly DN-NIK in vivo, 293T cells were co-transfected with Myc-IKKalpha and wt or aly DN-NIK expression vectors, lysed in non-ionic detergent, and immune-precipitated with anti-Myc antibody followed by immune blotting for NIK. The efficiency of the Myc-IKKalpha IP was about 10% (data not shown). wt DN-NIK was readily detected in the immune precipitate, whereas aly DN-NIK was not detectable (Fig. 6B). Thus, the aly mutation results in virtually complete loss of interaction or association of DN-NIK with IKKalpha .

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The data presented here indicate that LMP1, LMP1/LTbeta R, and LMP1/CD40 activate NF-kappa B similarly in wild type and aly/aly murine embryo fibroblasts. Therefore, NIK either does not have a direct role in NF-kappa B activation from any of these receptor cytoplasmic domains in MEFs, or another kinase substitutes for NIK in the transfected aly/aly fibroblasts and is unable to substitute under more physiologic conditions in vivo. Although this latter possibility seems a priori unlikely, similar substitution effects have been noted among MAP kinases in yeast, for example (28-33). Further, the similarity between the aly/aly and LTbeta R-/- phenotypes is most consistent with a physiologically significant role for the aly mutation in LTbeta R signaling. Moreover, the inability of the aly DN-NIK to specifically block LMP1 and LMP1/LTbeta R activation of NF-kappa B in 293 cells supports the notion that these cytoplasmic domains signal through a pathway that is specifically blocked by wt and not by aly DN-NIK. Indeed, the biochemical studies further support the hypothesis that the effect is at the level of NIK per se, in indicating that aly hNIK is most abnormal in loss of interaction with IKKalpha , is not abnormal in interaction with TRAF1, 2, 3, or 6, and is only minimally evident in diminished very weak interaction with IKKbeta .

The simplest explanation of the inability of the aly DN-NIK to block LMP1 or LMP1/LTbeta R activation of NF-kappa B is that aly NIK is unable to bind to an essential mediator of that pathway. The aly mutation is within the NIK TRAF binding domain, and the failure of aly NIK to block some TNFRs has been attributed to a putative affect of the aly mutation on TRAF binding. Our data indicate that the aly mutation does not affect NIK binding to or association with TRAF1, 2, 3, or 6, making it less likely that the aly effect is at the level of TRAF interaction with NIK. Instead, we find aly NIK to be highly deficient in binding to IKKalpha and that both wt and aly mutant NIK bind poorly to IKKbeta . Thus, the ability of wt NIK and the inability of aly NIK to block NF-kappa B activation from LMP1 or LMP1/LTbeta R are most consistent with a key role for a NIK-like kinase and IKKalpha in LMP1 and LTbeta R activation of NF-kappa B. Further, the blockade of CD40 and LMP1/CD40 activation of NF-kappa B by both wt and aly DN-NIK are most compatible with the possibility that CD40 signaling through the IKK complex is mediated by a protein that can be blocked by either the wt or aly NIK C terminus.

During the preparation of this manuscript, two publications appeared that are relevant to these experiments. In one, NIK is found to associate with the p100 precursor to the NF-kappa B subunit p52 and induce its phosphorylation and proteolytic processing (34). aly NIK, however, is unable to associate with p100 or induce p100 phosphorylation and processing (34). Consistent with these observations, p52 is not detected in aly/aly cells, despite the presence of p100 (34, 35). However, although p52-/- mice have major defects in germinal center formation and splenic architecture similar to aly/aly and LTbeta R-/- mice, serum Ig levels and proliferation in response to LPS and CD40L appear relatively normal in p52-/- mice but are abnormal in aly/aly mice (36, 37). Therefore, the deficiency in p100 processing is likely to account for only part of the aly/aly phenotype. In a second very recent paper, B cells from IKKalpha -/- mice are found to be quite similar to aly/aly B cells in their response to LPS and CD40L (38). This report is consistent with our finding that aly NIK is unable to interact with IKKalpha . Moreover, serum Ig levels are depressed in IKKalpha -/- bone marrow chimeras and in aly/aly mice but not in p52-/- mice (38). Thus, the inability of aly NIK to process p100 into p52 and the inability of aly NIK to interact with IKKalpha may both contribute to the aly/aly phenotype.

    ACKNOWLEDGEMENTS

We thank Drs. R. Shinkura, T. Honjo, J. Inoue, E. Hung, B. Sylla, P. Howley, E. Cooper, and D. Goeddel for reagents. Also, we are grateful for helpful comments and discussion from the Kieff laboratory.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA47006.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Biomedical Sciences Research Center "Al Fleming", Institute of Immunology, 14-16 Al Fleming Str., Vari, 16672, Athens, Greece.

§ To whom correspondence should be addressed. Tel.: 617-525-4250; Fax: 617-525-4251; E-mail: ekieff@rics.bwh.harvard.edu.

Published, JBC Papers in Press, March 14, 2001, DOI 10.1074/jbc.C100103200

2 M. L. and E. K., unpublished observations.

    ABBREVIATIONS

The abbreviations used are: NIK, NF-kappa B-inducing kinase; h, human; LPS, lipopolysaccharide; IKK, Ikappa B kinase; TNFR(s), tumor necrosis factor receptor (s); TRAF, TNFR-associated factor; DN-NIK, dominant negative hNIK (aa 624-947); GST, glutathione S-transferase; LMP1, Epstein-Barr virus latent membrane protein 1; LTbeta R, lymphotoxin beta  receptor; IB, immunoblotting; MEF(s), mouse embryo fibroblast(s); F, FLAG-tagged; IVT(s), in vitro translation(s); EBV, Epstein-Barr virus; PCR, polymerase chain reaction; wt, wild type; luc, luciferase; PAGE, polyacrylamide gel electrophoresis; aa, amino acid; IP, immunoprecipitation; MAP, mitogen-activated protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. (1997) Nature 385, 540-544[CrossRef][Medline] [Order article via Infotrieve]
2. Song, H. Y., Regnier, C. H., Kirschning, C. J., Goeddel, D. V., and Rothe, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 9792-9796[Abstract/Free Full Text]
3. Lin, X., Mu, Y., Cunningham, E. T., Marcu, K. B., Geleziunas, R., and Greene, W. C. (1998) Mol. Cell. Biol. 18, 5899-5907[Abstract/Free Full Text]
4. Ling, L., Cao, Z., and Goeddel, D. V. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3792-3797[Abstract/Free Full Text]
5. Li, Z. W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M., Johnson, R., and Karin, M. (1999) J. Exp. Med. 189, 1839-1845[Abstract/Free Full Text]
6. Delhase, M., Hayakawa, M., Chen, Y., and Karin, M. (1999) Science 284, 309-313[Abstract/Free Full Text]
7. Sylla, B. S., Hung, S. C., Davidson, D. M., Hatzivassiliou, E., Malinin, N. L., Wallach, D., Gilmore, T. D., Kieff, E., and Mosialos, G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10106-10111[Abstract/Free Full Text]
8. Geleziunas, R., Ferrell, S., Lin, X., Mu, Y., Cunningham, E. T., Grant, M., Connelly, M. A., Hambor, J. E., Marcu, K. B., and Greene, W. C. (1998) Mol. Cell. Biol. 18, 5157-5165[Abstract/Free Full Text]
9. Darnay, B. G., Ni, J., Moore, P. A., and Aggarwal, B. B. (1999) J. Biol. Chem. 274, 7724-7731[Abstract/Free Full Text]
10. Lin, X., Cunningham, E. T., Mu, Y., Geleziunas, R., and Greene, W. C. (1999) Immunity 10, 271-280[Medline] [Order article via Infotrieve]
11. Natoli, G., Costanzo, A., Moretti, F., Fulco, M., Balsano, C., and Levrero, M. (1997) J. Biol. Chem. 272, 26079-26082[Abstract/Free Full Text]
12. Shinkura, R., Kitada, K., Matsuda, F., Tashiro, K., Ikuta, K., Suzuki, M., Kogishi, K., Serikawa, T., and Honjo, T. (1999) Nat. Genet. 22, 74-77[CrossRef][Medline] [Order article via Infotrieve]
13. Garceau, N., Kosaka, Y., Masters, S., Hambor, J., Shinkura, R., Honjo, T., and Noelle, R. J. (2000) J. Exp. Med. 191, 381-386[Abstract/Free Full Text]
14. Futterer, A., Mink, K., Luz, A., Kosco-Vilbois, M. H., and Pfeffer, K. (1998) Immunity 9, 59-70[Medline] [Order article via Infotrieve]
15. Matsumoto, M., Iwamasa, K., Rennert, P. D., Yamada, T., Suzuki, R., Matsushima, A., Okabe, M., Fujita, S., and Yokoyama, M. (1999) J. Immunol. 163, 1584-1591[Abstract/Free Full Text]
16. Kieff, E. (1996) in Virology (Fields, B. N. , Knipe, D. M. , Howley, P. M. , Chanock, R. M. , Melnick, J. L. , Monath, T. P. , Roizman, B. , and Straus, S., eds), 3rd Ed. , pp. 2343-2396, Raven Press, Ltd., Philadelphia, PA
17. Cahir McFarland, E. D., Izumi, K. M., and Mosialos, G. (1999) Oncogene 18, 6959-6964[CrossRef][Medline] [Order article via Infotrieve]
18. Devergne, O., Hatzivassiliou, E., Izumi, K. M., Kaye, K. M., Kleijnen, M. F., Kieff, E., and Mosialos, G. (1996) Mol. Cell. Biol. 16, 7098-7108[Abstract]
19. Izumi, K. M., and Kieff, E. D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12592-12597[Abstract/Free Full Text]
20. Hatzivassiliou, E., Miller, W. E., Raab-Traub, N., Kieff, E., and Mosialos, G. (1998) J. Immunol. 160, 1116-1121[Abstract/Free Full Text]
21. Evan, G. I., Lewis, G. K., Ramsay, G., and Bishop, J. M. (1985) Mol. Cell. Biol. 5, 3610-3616[Medline] [Order article via Infotrieve]
22. Huen, D. S., Henderson, S. A., Croom-Carter, D., and Rowe, M. (1995) Oncogene 10, 549-560[Medline] [Order article via Infotrieve]
23. Mitchell, T., and Sugden, B. (1995) J. Virol. 69, 2968-2976[Abstract]
24. Chen, L., Ashe, S., Singhal, M. C., Galloway, D. A., Hellstrom, I., and Hellstrom, K. E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6523-6527[Abstract]
25. Foehr, E. D., Bohuslav, J., Chen, L. F., DeNoronha, C., Geleziunas, R., Lin, X., O'Mahony, A., and Greene, W. C. (2000) J. Biol. Chem. 275, 34021-34024[Abstract/Free Full Text]
26. Devin, A., Cook, A., Lin, Y., Rodriguez, Y., Kelliher, M., and Liu, Z. (2000) Immunity 12, 419-429[Medline] [Order article via Infotrieve]
27. Woronicz, J. D., Gao, X., Cao, Z., Rothe, M., and Goeddel, D. V. (1997) Science 278, 866-869[Abstract/Free Full Text]
28. Kranz, J. E., Satterberg, B., and Elion, E. A. (1994) Genes Dev. 8, 313-327[Abstract]
29. Elion, E. A. (1998) Science 281, 1625-1626[Free Full Text]
30. Lee, B. N., and Elion, E. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12679-12684[Abstract/Free Full Text]
31. Madhani, H. D., Styles, C. A., and Fink, G. R. (1997) Cell 91, 673-684[Medline] [Order article via Infotrieve]
32. Madhani, H. D., and Fink, G. R. (1998) Trends Genet. 14, 151-155[CrossRef][Medline] [Order article via Infotrieve]
33. Madhani, H. D., and Fink, G. R. (1997) Science 275, 1314-1317[Abstract/Free Full Text]
34. Xiao, G., Harhaj, E. W., and Sun, S. C. (2001) Mol. Cell 7, 401-409[Medline] [Order article via Infotrieve]
35. Yamada, T., Mitani, T., Yorita, K., Uchida, D., Matsushima, A., Iwamasa, K., Fujita, S., and Matsumoto, M. (2000) J. Immunol. 165, 804-812[Abstract/Free Full Text]
36. Caamano, J. H., Rizzo, C. A., Durham, S. K., Barton, D. S., Raventos-Suarez, C., Snapper, C. M., and Bravo, R. (1998) J. Exp. Med. 187, 185-196[Abstract/Free Full Text]
37. Franzoso, G., Carlson, L., Poljak, L., Shores, E. W., Epstein, S., Leonardi, A., Grinberg, A., Tran, T., Scharton-Kersten, T., Anver, M., Love, P., Brown, K., and Siebenlist, U. (1998) J. Exp. Med. 187, 147-159[Abstract/Free Full Text]
38. Kaisho, T., Takeda, K., Tohru, T., Kawai, T., Nomura, F., Terada, N., and Akira, S. (2001) J. Exp. Med. 193, 417-426[Abstract/Free Full Text]
39. Xiao, G., and Sun, S. C. (2000) J. Biol. Chem. 275, 21081-21085[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.